2Arsenian MA. Carnitire and its drivatives in cardiovascular disease[J]. Prog Cardiovas Dis, 1997, 40,265-266.
3Sassen LM ,Bezstavasti K,vander Giessen WJ. L-propiongl Carnitine increases post ischemic blood flow but does not affect recovery of energy charge[J]. AM Physiol, 1991,26: H172-173.
4Bartels GL,Remme WJ,Se Hohe HR. Acute myocardial is chemia induces cardiac carnitine release in man[J]. Eur Heart, 1997,18: 84-90.
5Bremer J. Carnitine metabolism and function [J]. Physiol Res, 1983,63:1420-1428.
6Regitz V, Shug AL, Fleck E. Defective myocardial metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary hypertensive and valvular heart disease[J]. Am J Cardiol,1990,65: 755-803.
7Yusuf S, Sleight P, Pogue J, et al. Effects of angiotensin-converting enzyme, ramipil, on cardiovascular events in high 0risk patients. The Heart Outcomes Prevention Evaluation Study Investigators[J]. N Engl J Med, 2000,342(3):145-153.
8Pott B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J]. N Engl J Med, 1999,341;709-717.
9Anand I , Chandranshekhan Y , De Giuli F , et al. Acute and chronic effects of propionyl-carnitine on the hemodynamics, exercise capacity , and hormones in patients with congestive heart failure[J]. Cardiovasc Drugs Ther, 1988,12:291-308.
